drugset / Trial / NCT07580339
Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer
Phase 2
Not yet recruiting
30 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DynamiCure Biotechnology · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and clinical activity of combining DCSZ11 with radiation and capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with mismatch repair proficient (pMMR) high risk locally advanced rectal cancer.
Timeline
- Start
- 2026-07
- Primary completion
- 2030-07
- Completion
- 2030-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | DCSZ11 | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |